Valneva Announces Positive Immunogenicity And Safety Data For Lyme Vaccine
Sept 3 (Reuters) - Valneva SE VLS.PA:
ANNOUNCES POSITIVE IMMUNOGENICITY AND SAFETY DATA FOR LYME VACCINE
VLA15-221 PHASE 2 STUDY SHOWS SIGNIFICANT ANTIBODY RESPONSE ACROSS SEROTYPES
PFIZER AIMS TO SUBMIT BLA TO FDA AND MAA TO EMA IN 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Intel Foundry Gains ‘High-Profile’ Customer, Tesla Becomes First Major Customer for 14A Technology

Anthropic Eclipses OpenAI in Secondary Market as Valuation Hits $1 Trillion Milestone, Is the AI Market Overheating Now?

Robinhood Stock Predictions: Can HOOD Reach the $1,000 Milestone?

Tesla Officially Announces. Third-Generation Humanoid Robot to Debut Mid-Year, Mass Production to Start in Third Quarter

Intel Better-Than-Expected Earnings Released, Stock Surges 20% After-Hours, AI Computing Power Enters CPU Moment?

Tradingkey








